Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic GastritisReportar como inadecuado




Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Introduction

Autoimmune chronic atrophic gastritis CAG causes hypochlorhydria and hypergastrinaemia, which can lead to enterochromaffin-like ECL cell hyperplasia and gastric neuroendocrine tumours type 1 gastric NETs. Most behave indolently, but some larger tumours metastasise. Antrectomy, which removes the source of the hypergastrinaemia, usually causes tumour regression. Non-clinical and healthy-subject studies have shown that netazepide YF476 is a potent, highly selective and orally-active gastrin-CCK-2 receptor antagonist. Also, it is effective in animal models of ECL-cell tumours induced by hypergastrinaemia.

Aim

To assess the effect of netazepide on tumour biomarkers, number and size in patients with type I gastric NETs.

Methods

We studied 8 patients with multiple tumours and raised circulating gastrin and chromogranin A CgA concentrations in an open trial of oral netazepide for 12 weeks, with follow-up 12 weeks later. At 0, 6, 12 and 24 weeks, we carried out gastroscopy, counted and measured tumours, and took biopsies to assess abundances of several ECL-cell constituents. At 0, 3, 6, 9, 12 and 24 weeks, we measured circulating gastrin and CgA and assessed safety and tolerability.

Results

Netazepide was safe and well tolerated. Abundances of CgA p<0.05, histidine decarboxylase p<0.05 and matrix metalloproteinase-7p<0.10 were reduced at 6 and 12 weeks, but were raised again at follow-up. Likewise, plasma CgA was reduced at 3 weeks p<0.01, remained so until 12 weeks, but was raised again at follow-up. Tumours were fewer and the size of the largest one was smaller p<0.05 at 12 weeks, and remained so at follow-up. Serum gastrin was unaffected.

Conclusion

The reduction in abundances, plasma CgA, and tumour number and size by netazepide show that type 1 NETs are gastrin-dependent tumours. Failure of netazepide to increase serum gastrin further is consistent with achlorhydria. Netazepide is a potential new treatment for type 1 NETs. Longer, controlled trials are justified.

Trial Registration

European Union EudraCT database 2007-002916-24 https:-www.clinicaltrialsregister.eu-ctr-search-search?query=2007-002916-24 ClinicalTrials.gov NCT01339169 http:-clinicaltrials.gov-ct2-show-NCT01339169?term=yf476andrank=5



Autor: Andrew R. Moore, Malcolm Boyce, Islay A. Steele, Fiona Campbell, Andrea Varro, D. Mark Pritchard

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados